Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

July 21, 2022

Study Completion Date

September 1, 2022

Conditions
Mental DisorderMetabolic DisturbanceFeasibilityOverweight and ObesityLiraglutide
Interventions
DRUG

liraglutide 3 mg (Saxenda®) once-daily

Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.

Trial Locations (1)

4000

Psychiatric Centre Sct.Hans. Forensic Mental Health Services in the Capitol Region of Denmark., Roskilde

All Listed Sponsors
lead

Anders Fink-Jensen, MD, DMSci

OTHER